Abstract
The blood-brain barrier (BBB) poses a unique challenge for drug delivery to the central nervous system (CNS). The BBB consists of a continuous layer of specialized endothelial cells linked together by tight junctions, pericytes, nonfenestrated basal lamina, and astrocytic foot processes. This complex barrier controls and limits the systemic delivery of therapeutics to the CNS. Several innovative strategies have been explored to enhance the transport of therapeutics across the BBB, each with individual advantages and disadvantages. Ongoing advances in delivery approaches that overcome the BBB are enabling more effective therapies for CNS diseases. In this review, we discuss: (1) the physiological properties of the BBB, (2) conventional strategies to enhance paracellular and transcellular transport through the BBB, (3) emerging concepts to overcome the BBB, and (4) alternative CNS drug delivery strategies that bypass the BBB entirely. Based on these exciting advances, we anticipate that in the near future, drug delivery research efforts will lead to more effective therapeutic interventions for diseases of the CNS.
Keywords: Central Nervous System (CNS), Blood-Brain Barrier (BBB), nanotechnology, ultrasound, immunotherapy.
Current Pharmaceutical Design
Title:Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Volume: 22 Issue: 9
Author(s): David S. Hersh, Aniket S. Wadajkar, Nathan B. Roberts, Jimena G. Perez, Nina P. Connolly, Victor Frenkel, Jeffrey A. Winkles, Graeme F. Woodworth and Anthony J. Kim
Affiliation:
Keywords: Central Nervous System (CNS), Blood-Brain Barrier (BBB), nanotechnology, ultrasound, immunotherapy.
Abstract: The blood-brain barrier (BBB) poses a unique challenge for drug delivery to the central nervous system (CNS). The BBB consists of a continuous layer of specialized endothelial cells linked together by tight junctions, pericytes, nonfenestrated basal lamina, and astrocytic foot processes. This complex barrier controls and limits the systemic delivery of therapeutics to the CNS. Several innovative strategies have been explored to enhance the transport of therapeutics across the BBB, each with individual advantages and disadvantages. Ongoing advances in delivery approaches that overcome the BBB are enabling more effective therapies for CNS diseases. In this review, we discuss: (1) the physiological properties of the BBB, (2) conventional strategies to enhance paracellular and transcellular transport through the BBB, (3) emerging concepts to overcome the BBB, and (4) alternative CNS drug delivery strategies that bypass the BBB entirely. Based on these exciting advances, we anticipate that in the near future, drug delivery research efforts will lead to more effective therapeutic interventions for diseases of the CNS.
Export Options
About this article
Cite this article as:
Hersh S. David, Wadajkar S. Aniket, Roberts B. Nathan, Perez G. Jimena, Connolly P. Nina, Frenkel Victor, Winkles A. Jeffrey, Woodworth F. Graeme and Kim J. Anthony, Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier, Current Pharmaceutical Design 2016; 22 (9) . https://dx.doi.org/10.2174/1381612822666151221150733
DOI https://dx.doi.org/10.2174/1381612822666151221150733 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
Current Pharmaceutical Design Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine
Current Medicinal Chemistry Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Recent Gains in Clinical Multiple Sclerosis Research
CNS & Neurological Disorders - Drug Targets Gene Therapy for Wiskott-Aldrich Syndrome
Current Gene Therapy Endothelial Changes in Individuals with Prehypertension
Current Hypertension Reviews Cell Death Targets and Potential Modulators in Alzheimers Disease
Current Pharmaceutical Design Comparison of Clinical Features at the Onset of Takayasu’s Arteritis According to Age and Sex
Current Vascular Pharmacology In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Magnetic Resonance Angiography and Multidetector CT Angiography in the Diagnosis of Takayasu's Arteritis: Assessment of Disease Extent and Correlation with Disease Activity
Current Medical Imaging Rheumatological Diseases in HIV Infection
Current Rheumatology Reviews Substance Abuse and Movement Disorders
Current Drug Abuse Reviews Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India
Current Vascular Pharmacology Interventional Radiology in Paediatrics
Current Pediatric Reviews Shoulder Manifestations of Diabetes Mellitus
Current Diabetes Reviews New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Management of Vasculopathy in Connective Tissue Disease
Current Rheumatology Reviews Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety